Global R&D Organisation selects Centrus & SRS
29 May 2013
Embargoed for 07:00
Instem plc
("Instem", the "Company" or the "Group")
Centrus and SRS selected by Global R&D Organisation
Integrated solution provides data aggregation, regulatory submission and bioinformatics capabilities
Instem plc (AIM: INS.L), a leading provider of IT applications to the global early development healthcare market, today announces that a world leading healthcare company has purchased the complete Centrus™ software suite and is the first to order Centrus SRS, a comprehensive data integration and bioinformatics solution.
Centrus was launched in late 2010 and focuses on the areas of enterprise information integration in early drug development, management and reporting. The suite continues to build good momentum, particularly the modules associated with the US Food and Drug Administration sponsored Standard for the Exchange of Non-clinical Data (SEND). It is therefore very pleasing to see this Global R&D organisation purchasing the entire solution, including Centrus submit™ to satisfy their own business requirements while becoming compliant in meeting this important FDA-endorsed standard.
The acquisition of BioWisdom in March 2011 accelerated the development of the Centrus product suite and provided sophisticated technologies to aggregate, analyse and extract knowledge from huge volumes of disparate internal and external data, unlocking considerable additional value from billions of dollars of prior research investments. Centrus SRS is one of the latest examples of how Instem is integrating key technology platforms to meet the developing demand by clients for data-driven insights.
Using Centrus SRS, the client will be able to access, integrate and query data being created from their own preclinical studies as well as data received from their external study partners. This cross-study search and browsing capability enables the client to identify patterns and trends, generating important new knowledge and actionable insight quickly and cost-effectively.
During 2012 Instem was recognised at the CDISC Interchange North America meeting for its outstanding contributions toward the completion of the SEND 3.0 Implementation Guide. More recently Instem was delighted to have received the VOLTAGE Technology Innovator Award for its submit-SEND solution at a ceremony in Philadelphia in May 2013.
Phil Reason, CEO of Instem plc, further commented: "The SEND standard is expected to be a catalyst for the uptake of Centrus, as clients prioritise investments which satisfy new regulatory requirements and support increased study outsourcing. We are encouraged to see this client leverage its use of Centrus, and its other processes, through our comprehensive Data Integration & Bioinformatics technology platform, SRS. Our capabilities in this area are very strong, and the technology reaches across all stages of the process of drug discovery and development, not just our Early Development core market.
"Instem's addressable market has been further expanded through the acquisition of Logos Technologies, announced 13 May 2013. Entry into the early clinical market also provides greater access to early phase clinical data in both healthy and patient populations, enhancing the potential of Instem's translational informatics solutions."
For further information, please contact:
|
Instem plc |
+44 (0) 1785 825 600 |
|
Phil Reason, CEO |
|
|
Nigel Goldsmith, CFO |
|
|
|
|
|
N+1 Singer (Nominated Adviser & Broker) |
+44 (0) 20 7496 3000 |
|
Aubrey Powell |
|
|
Joe Stroud |
|
|
|
|
|
Newgate Threadneedle |
+44 (0) 20 7653 9850 |
|
Fiona Conroy |
|
|
Caroline Evans-Jones |
|
About Instem plc
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are used by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem supports its clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.
To learn more about Instem solutions and its mission, please visit www.instem.com or its investor centre http://investors.instem.com/
This information is provided by RNS
Latest directors dealings
- 8 hours ago ASOS
- 9 hours ago MJ Gleeson
- 9 hours ago Rolls-Royce Holdings
- 9 hours ago Crest Nicholson Holdings
- 10 hours ago Naked Wines